BVF PARTNERS L P/IL Form 3 April 16, 2003

| | | UN | NITED STATE | S SI | | | CHANGE COMMISSION | OM | OMB APPROVAL | | | |
|---|--|-------------------------|---------------|--|--|--------------------------------|--|--|--------------|---|--|--|
| F | FORM 3 BENE | | | Washington, D.C. 20549 INITIAL STATEMENT OF FICIAL OWNERSHIP OF SECURITIES | | | | OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response 0.5 | | | | |
| (Print or | r Type Response | s) | Section 17(a) | of th | | ng C | es Exchange Act of 1934, Company Act of 1935 or pany Act of 1940 | | | | | |
| Name and Addres BVF Partners L.P | | ss of Reporting Person* | | | Date of Event Requiring Statement (Month/Day/Year) | 4. | 4. Issuer Name and Ticker or Trading Symbol | | | | | |
| | | | | | April 14, 2003 | Array BioPharma, Inc. ("ARRY") | | | | | | |
| | (Last) | (First) | (Middle) | 3. | I.R.S. Identification Number of Reporting Person, if | 5. | Relationship of Reporting Pers Issuer (Check all applicable) | | | If Amendment, Date of Original (Month/Day/Year) | | |
| 227 We | st Monroe Street | et, Suite 4800 | | an entity (voluntary) | | | | <u>X</u> 10% Owner | | | | |
| Chicago, Illinois 60606 | | (Street) | | | | | (give title (| (specify below) | | Individual or Joint/Group Filing | | |
| | | | | - | | _ | | | | (Check Applicable Line) | | |
| (Ci | ity) | (State) | (Zip) | | | | | | | Form filed by One Reporting Person X Form filed by More than One Reporting Person | | |
| | | | Ta | ıble I | Non-Derivative Sec | curit | ies Beneficially Owned | | | | | |
| | Title of Security2.Amount of Beneficial (Instr. 4) | | | | | Ľ | Ownership Form: 4. Direct (D) or Indirect (I) (Instr. 5) | | | Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| Co | mmon Stock | | 2,939,735 | i | | (1 | [) | | (1) | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| *If the form is | iled by m | ore than one report | rting person, see In | nstruc | ction 5(b)(v). | | | | | | | |
|-----------------|-------------|---------------------------------|---|--------|----------------|---|--------|---------|--------|---------------|----|---|
| Reminder: Rep | ort on a se | parate line for eac | ch class of securitie | es ber | neficially ow | ned directly or | indi | rectly. | | | | |
| | | | | | | | | | | | | SEC 147 (03-99 |
| | | | | | | | ired | | | | | |
| | ess the fo | rm displays a cu | information cont rrently valid OMI Perivative Securiti | B con | trol number | r. wned (<i>e.g.</i> , pu | | | otions | , convertible | | Page 1 of |
| to respond un | ess the fo | rm displays a cui Table II D | rrently valid OMI Derivative Securiti le and Expiration | B con | trol number | r. wned (e.g., pu curities) mount of Underlying | ıts, c | | 5. | | 6. | Page 1 of Nature of Indirect Beneficial Ownership (Instr. 5) |

Explanation of Responses:

(1)

The shares reported in this response are directly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 3, and its general partner, BVF Inc., a Delaware Corporation ("BVF, Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P."), an investment limited partnership that directly beneficially owns 951,685 of the shares of Common Stock reported in Table I. Partners is also the general partner of Biotechnology Value Fund, II, L.P., a Delaware limited partnership ("BVF, L.P."), an investment limited partnership that directly beneficially owns 951,685 of the shares of Common Stock reported in Table I. Partners is also the general partner of Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2"), an investment limited partnership which directly beneficially owns 537,450 of the shares of Common Stock reported in Table I. Partners is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"), which beneficially owns 1,450,600 of the shares of Common Stock reported in Table I. Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments. Mark N. Lampert is, for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.

Edgar Filing: BVF PARTNERS L P/IL - Form 3

| BVF Part | iners L.P. |
|----------|------------|
|----------|------------|

| By: By: | BVF Inc., its general partner /s/ MARK N. LAMPERT | April 16, 2003 |
|------------|---|----------------|
| By. | ** Signature of Reporting Person | Date |

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

| | | Page 2 of 3 |
|---|---|----------------|
| FORM 3 (Continued) 1. Biotechnology Value Fund, L.P. | List of the names and addresses of other reporting persons: BIOTECHNOLOGY VALUE FUND, L.P. | |
| 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 | By: BVF Partners L.P., its general partner | |
| | By: BVF Inc., its general partner | |
| | By: /s/ MARK N. LAMPERT | April 16, 2003 |
| | **Signature of Reporting Person Authorized Signatory | Date |
| 2. Biotechnology Value Fund II, L.P. | BIOTECHNOLOGY VALUE FUND II, L.P. | |
| 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 | By: BVF Partners L.P., its general partner | |
| | By: BVF Inc., its general partner | |
| | By: /s/ MARK N. LAMPERT | April 16, 2003 |
| | **Signature of Reporting Person Authorized Signatory | Date |
| 3. BVF Investments, L.L.C. | BVF INVESTMENTS, L.L.C. | |
| 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 | By: BVF Partners L.P., its manager | |
| | By: BVF Inc., its general partner | |
| | By: /s/ MARK N. LAMPERT | April 16, 2003 |
| | **Signature of Reporting Person Authorized Signatory | Date |
| 4. BVF Inc. | BVF INC. | |
| One Sansome Street, 31st Floor San Francisco, California 94104 | By: /s/ MARK N. LAMPERT | April 16, 2003 |
| | **Signature of Reporting Person Authorized Signatory | Date |
| Mark N. Lampert One Sansome Street, 31st Floor | By: /s/ MARK N. LAMPERT | April 16, 2003 |
| San Francisco, California 94104 | **Signature of Reporting Person | Date |

Authorized Signatory

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: BVF PARTNERS L P/IL - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.